Epicrispr Raises $90 Million for EPI-321 Pivotal Path

Company: Epicrispr Biotechnologies · Event Type: Deal and Financing · Product/Asset: EPI-321 · Subject: Facioscapulohumeral Muscular Dystrophy · Event Date: August 11, 2026 Summary Epicrispr Biotechnologies closed an oversubscribed $90 million Series C co-led by Octagon Capital and Janus Henderson Investors. Proceeds are intended to…